Table 3. Cox proportional hazard analysis on progression-free survival and overall survival.
| Variable | Progression-free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age (yr) | ||||||
| ≤50 | 1 | 1 | ||||
| >50 | 1.436 | 0.751-2.747 | 0.274 | 1.093 | 0.513-2.331 | 0.819 |
| Histology | ||||||
| Squamous cell carcinoma | 1 | 1 | ||||
| AC/ASC | 1.719 | 0.837-3.530 | 0.140 | 2.332 | 1.021-5.326 | 0.044 |
| Stage at initial diagnosis | ||||||
| I-II | 1 | 1 | ||||
| III-IV | 0.884 | 0.420-1.863 | 0.747 | 1.228 | 0.555-2.717 | 0.612 |
| Second-line chemotherapy | ||||||
| CDDP based | 1 | 1 | ||||
| CDDP analogue based | 0.763 | 0.388-1.501 | 0.433 | 1.218 | 0.596-2.488 | 0.589 |
| Prior radiotherapy | ||||||
| Yes | 1 | 1 | ||||
| No | 1.020 | 0.265-3.925 | 0.977 | 0.744 | 0.091-6.102 | 0.783 |
| Pelvic disease | ||||||
| Yes | 1 | 1 | ||||
| No | 0.486 | 0.222-1.064 | 0.071 | 0.704 | 0.310-1.602 | 0.403 |
| Tumor diameter (mm) | ||||||
| <30 | 1 | 1 | ||||
| ≥30 | 3.800 | 1.789-8.070 | 0.001 | 1.529 | 0.708-3.304 | 0.280 |
| PFI<12months | ||||||
| Yes | 1 | 1 | ||||
| No | 0.336 | 0.141-0.802 | 0.014 | 0.365 | 0.146-0.917 | 0.032 |
AC/ASC, adenocarcinoma/adenosquamous cell carcinoma; CDDP, cisplatin; CI, confidence interval; HR, hazard ratio; PFI, platinum free interval.